key: cord-0297548-p305bcli authors: Chidambaram, V.; Tun, N. L.; Majella, M. G.; Castillo, J. R.; Ayeh, S. K.; Kumar, A.; Neupane, P.; Sivakumar, R. K.; Win, E. P.; Abbey, E. J.; Wang, S.; Zimmerman, A.; Blanck, J.; Gupte, A.; Wang, J.-Y.; Karakousis, P. C. title: Sex differences in TB treatment outcomes: Retrospective cohort study and meta-analysis date: 2021-04-28 journal: nan DOI: 10.1101/2021.04.26.21256155 sha: 7fef5601da7648fc738aa7370fa785f22936c07b doc_id: 297548 cord_uid: p305bcli Background Although the incidence of tuberculosis (TB) is higher in males compared to females, the relationship of sex with TB treatment outcomes has not been adequately studied. Methods We performed a retrospective cohort study and a systematic review and meta-analysis of observational studies during the last 10 years to assess the sex differences in clinical and microbiological outcomes in tuberculosis. Results In our cohort of 2,894 patients with drug-susceptible pulmonary TB (1,975 males and 919 females), males had higher adjusted hazards of mortality due to all causes (HR 1.43,95%CI 1.03-1.98) and infections (HR 1.70, 95%CI 1.09-2.64) at 9 months and higher adjusted odds ratio for sputum culture (OR 1.56,95%CI 1.05-2.33) and similar odds ratio for smear positivity (OR 1.27, 0.71-2.27) at 2 months compared to females. Among 7896 articles retrieved, 398 articles were included in our systematic review with a total of 3,957,216 patients. The odds of all-cause mortality was higher in males compared to females in the pooled unadjusted (OR 1.26, 95%CI 1.19-1.34) and adjusted (OR 1.31, 95%CI 1.18- 1.45) analyses. Relative to females, males had higher pooled odds of sputum culture (OR 1.44,95% CI 1.14-1.81) and sputum smear (OR 1.58,95%CI 1.41-1.77) positivity both at the end of the intensive phase and upon completion of treatment. Conclusions In patients with TB, males have a higher all-cause-, infection- and TB-related mortality, as well as higher rates of sputum smear and culture positivity, both after the intensive phase and at the completion of TB treatment, after adjusting for confounding factors. The World Health Organization reported nearly 10 million new cases of active tuberculosis(TB) in 2019(1). Although Mycobacterium tuberculosis(Mtb) infects both sexes and all age groups, adult men have a 1.8-fold higher incidence of active TB disease(1, 2). These sex disparities have been reported irrespective of geographical locale (3) , and studies have shown that the ratio of prevalence to notification of TB is nonetheless higher in men (4, 5) . Many potential medical and cultural confounding factors such as the increased prevalence of diabetes, alcohol use, and smoking among males, and decreased access to health care among females may account for sex differences in TB (1, 3) . Clinical studies have reported that men had higher sputum bacterial loads and greater severity of TB-related lung disease on chest imaging than women (6, 7) . A few population-based studies have shown male patients to have poor outcomes following tuberculosis(8, 9) . These clinical observations are supported by animal model data showing more extensive lung pathology, higher lung bacterial burdens, and accelerated mortality in males relative to females following Mtb infection (10, 11) . Although prior clinical observational studies have highlighted sex differences in TB disease, the findings are often unclear and inconsistent because of the inherent heterogeneity of study populations and the level of care in low-income countries, as well as due to the lack of disaggregated data related to sex in many studies. We analyzed a retrospective cohort of Taiwanese patients with drug-susceptible pulmonary TB to better understand the role of sex on mortality and sputum microbiological status after TB treatment initiation, after adjusting for common confounders. We also performed a systematic review and meta-analysis on this topic, given the lack of generalizability from individual cohort studies, and to better assess the impact of other important parameters, including HIV-coinfection status, site of TB involvement, level of drug resistance, duration of follow up, and study country on the effect of sex differences. confounding factors included in the CCI were not adjusted for separately if CCI was included in the multivariable analytical model. The systematic review was conducted according to the PRISMA guidelines (15) . The literature searches were performed in PubMed, Embase, and Web of Science on August 15, 2020, using the search strategy detailed in the supplementary document (Section I). We captured both research articles and letters in the English language published in the last ten years. We included only articles published in peer-reviewed academic journals; conference abstracts were not included. Studies were required to report sex-disaggregated data on at least one of the following outcomes on adult TB patients treated with multidrug anti-TB therapy (ATT): all-cause mortality, mortality due to TB, sputum AFB smear or culture positivity during or at the end of TB treatment, or 'treatment success' according to the WHO definitions for reporting TB outcomes(16). We included prospective and retrospective cohort studies and case-control studies. We excluded case reports, case series, and cross-sectional studies. We utilized the COVIDENCE platform for the systematic review (17) . After removing the duplicates, the titles and abstracts of the retrieved articles were screened by at least two authors (VC, NT, AK, or PN) independently and the disagreements were resolved by VC. At least two authors (VC, NT, AK, or MM) independently performed the full-text screening, and the conflicts were resolved by VC. At least two authors extracted data from the articles (VC, NT, MM, RK, SA, EW, EA, SW, or AZ) in the Qualtrics platform (18), and discrepancies were resolved by VC. Data on the country of study, funding source, patient comorbidities, site of TB involvement, pattern of resistance to ATT, HIV-TB co-infection, duration of treatment, and time points for outcomes were extracted. Data on treatment outcomes were extracted either as raw data or as pre-calculated effect sizes, namely odds ratio (OR), relative risk (RR), or hazard ratio (HR), along with 95% confidence interval (CI), as reported in the studies. RR for mortality in males compared to females was reported only in 7 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. ; https://doi.org/10.1101/2021.04.26.21256155 doi: medRxiv preprint studies, and were therefore converted to OR to facilitate pooling of the effect sizes(19). We performed quality assessment using the New-Castle Ottawa scale for observational studies(NOS)(20). For each of the outcomes, we performed a meta-analysis of the OR using the random-effects model. We pooled HR separately for each of the outcomes. We considered a two-sided probability of < 0.05 as significant. We assessed heterogeneity using the I 2 statistics. When the I 2 was > 60%, we performed subgroup analyses and meta-regression (Detailed in the supplementary document -Section IIa) with respect to the TB-HIV co-infection status, resistance to ATT, and extra-pulmonary involvement, time of outcome assessment, study country's income status classification according to World Bank(21), incidence of TB infection and HIV-TB co-infection(22). Publication bias was assessed by funnel plot and Egger's test. Statistical analyses were performed using STATA/IC 16.0 software (StataCorp, College Station, Texas)(23). The study protocol is registered with PROSPERO (CRD42020219050). The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. In our cohort of 2894 patients with culture-confirmed, drug-susceptible pulmonary TB, 1975 (68.2%) were males, and 919 (31.8%) were females (Table 1) . Males had a higher median age than females (68.9 years vs 58.2 years, p <0.001). A greater proportion of males had comorbidities, history of smoking, and alcohol abuse compared to females. Males had a greater proportion of cavitary disease (15.7% vs 11.1%; p<0.001) at diagnosis (Table 1) . Baseline sputum AFB smear positivity rates were similar in both sexes. During the first 9 months after ATT initiation, the log-rank test of the Kaplan-Meier analysis showed that males had significantly shorter survival compared to females ( Figure 1A ; p< 0.001). After adjusting for confounders such as BMI, CCI, COPD, alcoholism, smoking, cavitary disease (Table 2) , males had a HR of 1.43(95%CI 1.08-1.98) for all-cause mortality. Infection-related causes accounted for 55.7% (303/544 patients) of all deaths in the first 9 months (Table 2 ). In the Cox regression analysis, males had an adjusted HR of 1.70 (95%CI 1.09-2.64) for infection-related mortality ( Figure 1B ). Males had significantly higher sputum culture (18.4% vs 11.6%, p=0.003) and AFB smear (8.3% vs 5.0%, p=0.015) positivity at 2 months compared to females by chi 2 test, with a considerable difference primarily among individuals less than 50 years (Figure 2A and 2B). Multivariable logistic regression revealed higher odds of sputum-culture positivity in males (OR 1.56, 95%CI 1.05-2.33, p=0.03), but the odds of sputum AFB smear positivity rate (OR 1.27, 95%CI 0.71-2.27, p=0.42) was not different between the sexes at 2 months. Sensitivity analyses by additionally adjusting for age in the multivariable regression analyses also yielded similar results (Supplementary section III, Supplementary table 1) . Among the 7896 studies screened, we selected 740 studies for full text review ( Figure 3 ). Finally, data from 398 studies, reporting on a total of 3,957,216 individuals, were analyzed in our review (Supplementary table 2 Table 3 ). The pooled adjusted OR was 1.26 (95%CI 1.16-1.37) among 52 studies (I 2 =90.9%) and the pooled adjusted HR was 1.20 (95%CI 1.05-1.37) among 30 studies (I 2 =82.5%) ( Table 3) . Considerable heterogeneity was present in the meta-analyses of OR and HR for all-cause mortality. Studies reporting mortality of TB patients in the intensive care unit showed no significant difference in mortality when stratified by sex (Table 3 ). Further subgroup analyses were performed after excluding studies reporting outcomes in patients receiving intensive care (Table 4 ). Metaregression analysis showed that the timepoint used for assessing mortality did not change the . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 28, 2021. ; https://doi.org/10.1101/2021.04.26.21256155 doi: medRxiv preprint association between male sex and this outcome ( Figure 4 ). Detailed results of the subgroup and metaregression analysis on all-cause mortality are described in the supplementary document (Section IIb). We included 12 studies that reported death due to TB ( Table 5 ). The pooled OR for death due to TB for males compared to females was 1.28 (95%CI 1.1-1.6) in 10 studies and the pooled HR was 1.34 (95%CI 1.09-1.55) in 2 studies. The pooled OR for death due to non-TB causes for males compared to females with TB was 1.3(95%CI 1.1-1.7) in 6 studies. Males had a pooled unadjusted OR of 1.60 (95%CI 1.28-1.99) in 12 studies (I 2 =24.6%) and pooled adjusted OR of 1.81 (95%CI 1.39-2.34) in 4 studies (I 2 =0%) ( (Table 6 ). Our meta-analysis revealed that odds of treatment success was lower in males in the meta-analysis of both adjusted and unadjusted effect sizes (Supplementary Table 5 ). There was very low heterogeneity in the data related to sputum culture or AFB smear positivity. Thus, these outcomes did not warrant further subgroup analysis. In the meta-regression analysis, mean age of the population and the proportions of patients with diabetes mellitus, hypertension, alcohol abuse, smoking, cardiovascular events, COPD and HIV did not significantly modify the association between male sex and any of the outcomes assessed (Supplementary Table 6 ). Publication bias measured by Egger's test was not present for any of the outcomes (Supplementary Section IV). Findings from our retrospective cohort and systematic review, comprising a total of 398 peerreviewed publications from over 80 high-, middle-, and low-income countries, suggest that male sex is associated with higher all-cause mortality and death due to TB, both during treatment and during . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. ; 1 0 follow up after ATT. This association held true even after adjusted for confounders in the cohort study and during extensive meta-regression analysis in the systematic review. With respect to microbiological outcomes, males had higher positivity for Mtb by both AFB smear microscopy and culture, at the end of the intensive phase as well as at ATT completion. In addition, male sex was found to be associated with lower treatment success rates. Our cohort study only included patients with drug-susceptible pulmonary TB from Taiwan, which is a high-income country with excellent access to health care resources. Our systematic review helped to expand and corroborate our findings with countries with variable health care resources. The meta-regression analysis demonstrated that mortality in males compared to females was significantly higher in high-income countries than in low-or middle-income countries (Table 4 ). This suggests that sex differences in TB treatment outcomes are more apparent in high-income settings with minimal differences in healthcare access between the sexes. It has been widely believed that socioeconomic and cultural factors are responsible for the observed sex bias. Patient-related delays and health care system delays in the diagnosis of TB and initiation of ATT have been shown to be more pronounced in women(24-26) due to financial dependence on the family, fear of social isolation and accessing less qualified providers were considered as major reasons for these treatment delays(27-29). In a cohort of TB patients from Australia, males had significantly higher rates of hemoptysis, and loss of body weight. and were more likely to have a sputum smear and chest imaging performed, with earlier treatment initiation(30). Males had higher rates of abnormal chest X-ray and pleural effusion, and higher odds of TB-related and all-cause mortality in spite of comparable treatment completion rates between the sexes(30). These observations are consistent with the hypothesis that males exhibit more severe TB disease at presentation and have worse outcomes despite better healthcare access, and prompt treatment initiation. Similarly, in a cohort of non-smoking TB patients without comorbidities, Tan et al. demonstrated that despite the delay in treatment initiation in women, high-resolution computed tomography (CT) showed more severe lung damage in men at baseline (7) . Additionally, scoring of the CT images pre-and post-ATT showed a more rapid response to therapy in women than in men (7). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Likewise, in a study by Chu et al. of 594 non-smoking men and women with newly diagnosed TB, multivariate logistic regression analysis revealed that males had 2.7 times higher odds of cavitary disease, and lung injury scores (6) . In our cohort, men had disproportionately high rates of smoking and cavitary disease compared to women. Matsumoto et al. found that male current smokers had higher rates of cavitary disease compared to female smokers(31). This could be explained by increased expression of matrix metalloproteinase in the lungs in men(32). Furthermore, the presence of lung cavitation is known to be associated with delayed sputum conversion during ATT(33). In our cohort, male sex was associated with a higher odds of sputum culture positivity at 2 months of ATT, after adjusting for confounding factors, such as smoking and cavitary disease. Likewise, our systematic review showed higher pooled unadjusted and adjusted odds of sputum AFB smear and culture positivity in males following treatment initiation. These findings emphasize that male sex is a risk factor for unfavorable microbiological outcomes during ATT. The phenomenon that male sex predisposes to infectious diseases has been recognized in liver abscess due to Entamoeba histolytica(34, 35), respiratory and systemic infection due to Streptococcus pneumoniae(36), and higher mortality due to SARS(37) and COVID-19(38, 39). Although such differences have been noted in TB outcomes, these have been largely attributed to social, economic, and cultural determinants rather than biological ones. More recently, studies have demonstrated how sex hormones can differentially regulate female and male immune responses to pathogens(40). Yamamoto and colleagues reported that peritoneal macrophages derived from male mice exhibited reduced antimicrobial activity and promoted mycobacterial growth(41, 42). Testosterone was shown to reduce the expression of TLR4 (toll-like receptor 4) in mouse macrophages(43) and to have immunosuppressive effects by increasing inhibitory cytokines, reducing Ig production, and inhibiting T and B cell maturation(44-47). In contrast, estradiol has been shown to enhance macrophage activation(48); and in turn have a greater clearance of pneumococcal pneumonia in female mice(49). Various studies have shown more severe disease in male mice following nontuberculous mycobacteria and Mtb infections, manifested by higher lung bacillary burdens, increased mortality . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. ; https://doi.org/10.1101/2021.04.26.21256155 doi: medRxiv preprint and significantly increased levels of pro-inflammatory cytokines (10, 11) , consistent with an excessive inflammatory response in males relative to females(50). In the systematic review, males had a higher pooled OR of mortality in studies with exclusively HIV-negative TB patients when compared to that in studies on HIV-TB co-infected patients. Prior literature from Africa has shown that males had worse outcomes compared to females in HIV-negative patients, but better outcomes compared to females among HIV-co-infected patients(51, 52). Thus, HIV co-infection appears to reduce the potential protective effect of female sex on TB treatment outcomes. This conclusion aligns well with the evidence in pre-clinical models that immunomodulation is responsible for the difference in outcomes between males and females. Although men have a higher incidence of TB, women have an increased incidence of EPTB compared to men(53-55). In our systematic review, the rates of mortality in men compared to women did not significantly differ between the studies on PTB and studies on EPTB. In studies with varying proportions of PTB and EPTB, the proportion of EPTB in the study population did not modify the association between mortality and sex. Likewise, the drug sensitivity of the study participants to ATT did not have any impact on the higher mortality rates in males. Our study has several strengths. The large sample size of our cohort study aided in the analysis of various confounding factors, such as comorbidities and social habits. As the cohort data were obtained from a single institution, heterogeneity in treatment decisions were minimized. Our systematic review included 398 studies from 81 countries with variable health care access, allowing for generalizability of our results. The large number of studies on all-cause mortality in our systematic review enabled us to perform subgroup analyses and to arrive at various inferences. Our systematic review included several studies on MDR TB and XDR TB, enabling our conclusions to apply to those with drug-resistant TB. Several limitations are noted. In our cohort study, we were unable to assess parameters such as occupational history, symptoms at diagnosis, and delay in diagnosis. In our systematic review, the drug sensitivity characteristics, study setting, and time of outcome assessment varied widely and were not reported consistently among the included studies. Several studies in our review, performed from program registries, did not report data on baseline characteristics stratified by sex. During meta-. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. ; https://doi.org/10.1101/2021.04.26.21256155 doi: medRxiv preprint analysis of adjusted effect sizes, individual studies were adjusted for comparable but different parameters. As the cohorts spanned over long periods of time, the treatment regimens followed may not be uniform across studies. Our results have several important therapeutic implications. Recognizing the association between male sex and adverse treatment outcomes should inform medical decision-making in TB treatment programs and motivate further focused research into the biological (immunological and genetic) basis of these sex-based differences and in turn novel host-directed therapies to improve clinical, pathological, and microbiological outcomes during TB treatment in both sexes. We declare no competing interests. All the forest plots and figures are included in the supplementary document of the manuscript. Cohort datasets will be available on further communication to the corresponding author. The cohort study was supported by the National Institute of . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. ; . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. ; e 1 : C h a r a c t e r i s t i c s o f t h e s t u d y p a r t i c i p a n t s i n t h e r e t r o s p e c t i v e c o h o r t f r o m T a i w a n s t r a t i f i e d b y s e x ( N = 2 . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. 1 8 T a b l e 2 : A s s o c i a t i o n o f m a l e s e x w i t h t u b e r c u l o s i s t r e a t m e n t o u t c o m e s i n t h e r e t r o s p e c t i v e c o h o r t u s i n g C o x a n d L o g i s t i c r e g r e s s i o n m o d e l s ( N = 2 . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. T a b l e 3 : A s s o c i a t i o n o f m a l e s e x w i t h a l l -c a u s e m o r t a l i t y w h e n c o m p a r e d t o f e m a l e s a m o n g p a t i e n t s w i t h t u b e r c u l o s i s u s i n g r a n d o m e f f e c t s m e t a -a n a l y s i is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. l e 4 : S u b g r o u p a n a l y s i s o f t h e p o o l e d e f f e c t s i z e s f o r t h e a s s o c i a t i o n o f m a l e s e x w i t h a l l -c a u s e m o r t a l i t y w h e n c o m p a r e d t o f e m a l e s a m o n g p a t i e n t s w i t h t u b e r c u l o s i s . C h a r a c t e r i s t i c s P o o l e d O d d s R a t i o # P o o l e d H a z a r d R a t i . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. l e 5 : S t u d i e s r e p o r t i n g t h e a s s o c i a t i o n o f m a l e s e x w i t h d e a t h d u e t o T B a n d n o n -T B c a u s e s w h e n c o m p a r e d t o f e m a l e s i n p a t i e n t s w i t h t u b e r c u l o s i s A u t h o r ( Y e a r ) C o u n t r y T y p e D a t a H I V ( % ) S i t e M a l e s F e m a l e s O R / H R D e a t h d u e t o T B D e a t h d u e t o n o n -T B c a u s e s A l l -c a u s e m o r t a l i t y T i m e l i n . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. T a b l e 6 : A s s o c i a t i o n o f m a l e s e x w i t h S p u t u m s m e a r a n d s p u t u m c u l t u r e p o s i t i v i t y w h e n c o m p a r e d t o f e m a l e s a m o n g p a t i e n t s w i t h t u b e r c u l o s i s u s i n g r a n d o m e f f e c t s m e t a -a n a l y s i is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Global Tuberculosis Report Sexual Inequality in Tuberculosis Sex Differences in Tuberculosis Burden and Notifications in Low-and Middle-Income Countries: A Systematic Review and Meta-analysis Gender and tuberculosis: A comparison of prevalence surveys with notification data to explore sex differences in case detection Sex Disparity in Severity of Lung Lesions in Newly Identified Tuberculosis Is Age-Associated Sex influences the association between haemostasis and the extent of lung lesions in tuberculosis Gender differentials of pulmonary tuberculosis transmission and reactivation in an endemic area Sex differences in the C57BL/6 model of Mycobacterium tuberculosis infection The Influence of Sex Steroid Hormones in the Immunopathology of Experimental Pulmonary Tuberculosis Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis The Impact of Hypertension and Use of Calcium Channel Blockers on Tuberculosis Treatment Outcomes A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement Covidence systematic review software, Veritas Health Innovation